27/07/2026
π§ Early Detection Starts with Better Biomarkers.
Large artery atherosclerosis (LAA) is one of the leading causes of ischemic stroke, making early risk assessment more important than ever.
Relia Biotech, an cardiovascular disease POCT expert, have full range of testing items from cardiovascular risk prediction, early heart injury, acute myocardial infarction, thrombosis, prognosis assessment, etc.
We are excited to introduce our NEW FIA Test Kits:
πΉ MPO (Myeloperoxidase) β A key biomarker reflecting vascular inflammation and plaque instability.
πΉ LP-PLAβ (Lipoprotein-associated Phospholipase Aβ) β A well-established marker for vascular inflammation and atherosclerotic plaque activity.
π Clinical evidence shows:
β
MPO and LP-PLAβ levels are significantly elevated in patients with large artery atherosclerosis.
β
Both biomarkers are independent risk factors for LAA cerebral infarction.
β
Combined detection achieves an AUC of 0.896, providing excellent predictive performance for identifying high-risk patients.
β Testing method: Strep-avidin biotin immunofluorescence test
β Running time: 8 minutes
β Dilute/Buffer need: No (totally buffer-free design on whole blood sample)
β Certificate: CE/NMPA/FSC
π© We are looking for global distributors and any interest or inquiry, welcome to contact with us as below:
Website: www.reliabiotech.com/en
Mail: [email protected]
